Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 6/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | DUSP1 | P28562 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727851 | 1.00 | FFAR1 (0.52) | FFAR1DUSP3DNMT1PKMPOLB | |
| SCHEMBL13236136 | 0.85 | FFAR1 (0.71) | FFAR1DNMT1PKMPOLBPTPN1 | |
| SCHEMBL26661588 | 0.85 | FFAR1 (0.52) | FFAR1POLBCISD1MAOAKDM4E | |
| SCHEMBL26794059 | 0.85 | FFAR1 (0.59) | FFAR1DNMT1PKMPOLBPTPN1 | |
| SCHEMBL26661589 | 0.85 | FFAR1 (0.52) | FFAR1POLBCISD1MAOAKDM4E | |
| SCHEMBL12417242 | 0.83 | FFAR1 (0.64) | FFAR1POLBPTPN1CISD1MAOA | |
| SCHEMBL863491 | 0.83 | FFAR1 (0.48) | FFAR1PKMPOLBCISD1MAOA | |
| SCHEMBL9920145 | 0.82 | FFAR1 (0.53) | FFAR1PKMPOLBCISD1MAOA | |
| SCHEMBL7858386 | 0.79 | ALDH1A1 (0.53) | POLBMAPTLMNATHRB | |
| SCHEMBL1903789 | 0.79 | MMP3 (0.55) | POLBPTPN1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820764-B2 | Compound modulating GSK-3 activity | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2023-11-21 | — | — | US | disclosed |
| US-11820764-B2 | Compound modulating GSK-3 activity | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820764-B2 | Compound modulating GSK-3 activity | GSK3B, GSK3A, GSKIP | FFAR1 3450/4885DUSP3 94/4885DNMT1 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.